cagrilintide and semaglutide New in the August 14, 2025, issue of NEJM: ⁣ ⁣ Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial)⁣ ⁣ Cagrilintide– for Overweight Diabetes (REDEFINE 2 phase 3a trial)⁣ ⁣ Cagrilintide and semaglutide act individually

Unlike manufactured branded medications, compounded semaglutide formulations require a valid prescription from a licensed healthcare provider and should only be dispensed by accredited pharmacies with quality assurance protocols in place

Chronic low-grade inflammation (inflammaging) is increasingly recognized as a driver of age-related disease, and BPC-157s ability to modulate inflammatory pathways may have broader implications for healthy aging

Anxiety afflicts 2545% of chronic liver disease patients, while depression affects a staggering 2972% (41)

L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions